The Evolution of Platelet Aggregability in Patients Undergoing Catheter Ablation for Supraventricular Tachycardia with Radiofrequency Energy

The Role of Antiplatelet Therapy

TZONG‐LUEN WANG, JIUNN‐LEE LIN, JUEY‐JEN HWANG, CHUEN‐DEN TSENG, HUEY‐MIN LO, WEN‐PIN LIEN, YUNG‐ZU TSENG

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Forty‐two consecutive patients were checked for profiles of platelet aggregability before, during, and 10 and 30 minutes after catheter ablation. They were randomized into Group A (n = 20) who accepted intravenous aspirin (in 0.015 g/kg body weight) and Group P (n = 22) who accepted only placebo treatment. Blood samples were drawn from ascending aorta (Ao) and main pulmonary artery (MPA) simultaneously at each time period. In Group P, the EC50 of substrate induced platelet aggregability decreases significantly during (for ADP, from 1.72 to 0.78/mol/L for samples from Ao, P ± 0.0001; and from 1.68 to 0.69 μmol/ Lfor MPA, P ± 0.0001; for collagen, from 2.26 to 1.34 μg/mLfor Ao, P ± 0.005, and from 2.40 to 1.64 μg/mL, P ± 0.0001) and 10 minutes after successful ablation (for ADP, to 0.70 μmol/L for Ao, P ± 0.000, and to 0.61 μmol/L for MPA, P ± 0.0001; for collagen, to 1.54 μg/mL for Ao, P ± 0.01, and to 1.63 μg/ mL, P ± 0.0001), and then returned to baseline levels 30 minutes later (all P = NS) compared with comparative baseline levels. The levels of thromboxane B2 (TXB2) had the similar evolution. The evolution of platelet aggregability profiles was not associated with total energy dose, duration of energy application, duration of procedure, impedance, and ablation site. However, there were moderate positive correlations between the TXB2 levels and tip temperatures (r = 0.56, P ± 0.05 for Ao and r = 0.65, P ± 0.01 for MPA). These results suggest that increased platelet aggregability can occur during and 10 minutes after radiofrequency current ablation and antiplatelet therapy can maintain “flat” response of platelet aggregability to radiofrequency energy, which may provide possible benefits in preventing the occurrence of the complication.

Original languageEnglish
Pages (from-to)1980-1990
Number of pages11
JournalPacing and Clinical Electrophysiology
Volume18
Issue number11
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Supraventricular Tachycardia
Catheter Ablation
Aorta
Blood Platelets
Pulmonary Artery
Thromboxane B2
Adenosine Diphosphate
Collagen
Therapeutics
Electric Impedance
Aspirin
Placebos
Body Weight
Temperature

Keywords

  • catheter ablation
  • platelet aggregability
  • radiofrequency
  • Supraventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The Evolution of Platelet Aggregability in Patients Undergoing Catheter Ablation for Supraventricular Tachycardia with Radiofrequency Energy : The Role of Antiplatelet Therapy. / WANG, TZONG‐LUEN; LIN, JIUNN‐LEE; HWANG, JUEY‐JEN; TSENG, CHUEN‐DEN; LO, HUEY‐MIN; LIEN, WEN‐PIN; TSENG, YUNG‐ZU.

In: Pacing and Clinical Electrophysiology, Vol. 18, No. 11, 01.01.1995, p. 1980-1990.

Research output: Contribution to journalArticle

WANG, TZONG‐LUEN ; LIN, JIUNN‐LEE ; HWANG, JUEY‐JEN ; TSENG, CHUEN‐DEN ; LO, HUEY‐MIN ; LIEN, WEN‐PIN ; TSENG, YUNG‐ZU. / The Evolution of Platelet Aggregability in Patients Undergoing Catheter Ablation for Supraventricular Tachycardia with Radiofrequency Energy : The Role of Antiplatelet Therapy. In: Pacing and Clinical Electrophysiology. 1995 ; Vol. 18, No. 11. pp. 1980-1990.
@article{8a8874700f1141f9b7bf3348da411f95,
title = "The Evolution of Platelet Aggregability in Patients Undergoing Catheter Ablation for Supraventricular Tachycardia with Radiofrequency Energy: The Role of Antiplatelet Therapy",
abstract = "Forty‐two consecutive patients were checked for profiles of platelet aggregability before, during, and 10 and 30 minutes after catheter ablation. They were randomized into Group A (n = 20) who accepted intravenous aspirin (in 0.015 g/kg body weight) and Group P (n = 22) who accepted only placebo treatment. Blood samples were drawn from ascending aorta (Ao) and main pulmonary artery (MPA) simultaneously at each time period. In Group P, the EC50 of substrate induced platelet aggregability decreases significantly during (for ADP, from 1.72 to 0.78/mol/L for samples from Ao, P ± 0.0001; and from 1.68 to 0.69 μmol/ Lfor MPA, P ± 0.0001; for collagen, from 2.26 to 1.34 μg/mLfor Ao, P ± 0.005, and from 2.40 to 1.64 μg/mL, P ± 0.0001) and 10 minutes after successful ablation (for ADP, to 0.70 μmol/L for Ao, P ± 0.000, and to 0.61 μmol/L for MPA, P ± 0.0001; for collagen, to 1.54 μg/mL for Ao, P ± 0.01, and to 1.63 μg/ mL, P ± 0.0001), and then returned to baseline levels 30 minutes later (all P = NS) compared with comparative baseline levels. The levels of thromboxane B2 (TXB2) had the similar evolution. The evolution of platelet aggregability profiles was not associated with total energy dose, duration of energy application, duration of procedure, impedance, and ablation site. However, there were moderate positive correlations between the TXB2 levels and tip temperatures (r = 0.56, P ± 0.05 for Ao and r = 0.65, P ± 0.01 for MPA). These results suggest that increased platelet aggregability can occur during and 10 minutes after radiofrequency current ablation and antiplatelet therapy can maintain “flat” response of platelet aggregability to radiofrequency energy, which may provide possible benefits in preventing the occurrence of the complication.",
keywords = "catheter ablation, platelet aggregability, radiofrequency, Supraventricular tachycardia",
author = "TZONG‐LUEN WANG and JIUNN‐LEE LIN and JUEY‐JEN HWANG and CHUEN‐DEN TSENG and HUEY‐MIN LO and WEN‐PIN LIEN and YUNG‐ZU TSENG",
year = "1995",
month = "1",
day = "1",
doi = "10.1111/j.1540-8159.1995.tb03857.x",
language = "English",
volume = "18",
pages = "1980--1990",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The Evolution of Platelet Aggregability in Patients Undergoing Catheter Ablation for Supraventricular Tachycardia with Radiofrequency Energy

T2 - The Role of Antiplatelet Therapy

AU - WANG, TZONG‐LUEN

AU - LIN, JIUNN‐LEE

AU - HWANG, JUEY‐JEN

AU - TSENG, CHUEN‐DEN

AU - LO, HUEY‐MIN

AU - LIEN, WEN‐PIN

AU - TSENG, YUNG‐ZU

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Forty‐two consecutive patients were checked for profiles of platelet aggregability before, during, and 10 and 30 minutes after catheter ablation. They were randomized into Group A (n = 20) who accepted intravenous aspirin (in 0.015 g/kg body weight) and Group P (n = 22) who accepted only placebo treatment. Blood samples were drawn from ascending aorta (Ao) and main pulmonary artery (MPA) simultaneously at each time period. In Group P, the EC50 of substrate induced platelet aggregability decreases significantly during (for ADP, from 1.72 to 0.78/mol/L for samples from Ao, P ± 0.0001; and from 1.68 to 0.69 μmol/ Lfor MPA, P ± 0.0001; for collagen, from 2.26 to 1.34 μg/mLfor Ao, P ± 0.005, and from 2.40 to 1.64 μg/mL, P ± 0.0001) and 10 minutes after successful ablation (for ADP, to 0.70 μmol/L for Ao, P ± 0.000, and to 0.61 μmol/L for MPA, P ± 0.0001; for collagen, to 1.54 μg/mL for Ao, P ± 0.01, and to 1.63 μg/ mL, P ± 0.0001), and then returned to baseline levels 30 minutes later (all P = NS) compared with comparative baseline levels. The levels of thromboxane B2 (TXB2) had the similar evolution. The evolution of platelet aggregability profiles was not associated with total energy dose, duration of energy application, duration of procedure, impedance, and ablation site. However, there were moderate positive correlations between the TXB2 levels and tip temperatures (r = 0.56, P ± 0.05 for Ao and r = 0.65, P ± 0.01 for MPA). These results suggest that increased platelet aggregability can occur during and 10 minutes after radiofrequency current ablation and antiplatelet therapy can maintain “flat” response of platelet aggregability to radiofrequency energy, which may provide possible benefits in preventing the occurrence of the complication.

AB - Forty‐two consecutive patients were checked for profiles of platelet aggregability before, during, and 10 and 30 minutes after catheter ablation. They were randomized into Group A (n = 20) who accepted intravenous aspirin (in 0.015 g/kg body weight) and Group P (n = 22) who accepted only placebo treatment. Blood samples were drawn from ascending aorta (Ao) and main pulmonary artery (MPA) simultaneously at each time period. In Group P, the EC50 of substrate induced platelet aggregability decreases significantly during (for ADP, from 1.72 to 0.78/mol/L for samples from Ao, P ± 0.0001; and from 1.68 to 0.69 μmol/ Lfor MPA, P ± 0.0001; for collagen, from 2.26 to 1.34 μg/mLfor Ao, P ± 0.005, and from 2.40 to 1.64 μg/mL, P ± 0.0001) and 10 minutes after successful ablation (for ADP, to 0.70 μmol/L for Ao, P ± 0.000, and to 0.61 μmol/L for MPA, P ± 0.0001; for collagen, to 1.54 μg/mL for Ao, P ± 0.01, and to 1.63 μg/ mL, P ± 0.0001), and then returned to baseline levels 30 minutes later (all P = NS) compared with comparative baseline levels. The levels of thromboxane B2 (TXB2) had the similar evolution. The evolution of platelet aggregability profiles was not associated with total energy dose, duration of energy application, duration of procedure, impedance, and ablation site. However, there were moderate positive correlations between the TXB2 levels and tip temperatures (r = 0.56, P ± 0.05 for Ao and r = 0.65, P ± 0.01 for MPA). These results suggest that increased platelet aggregability can occur during and 10 minutes after radiofrequency current ablation and antiplatelet therapy can maintain “flat” response of platelet aggregability to radiofrequency energy, which may provide possible benefits in preventing the occurrence of the complication.

KW - catheter ablation

KW - platelet aggregability

KW - radiofrequency

KW - Supraventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=0028876456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028876456&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.1995.tb03857.x

DO - 10.1111/j.1540-8159.1995.tb03857.x

M3 - Article

VL - 18

SP - 1980

EP - 1990

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 11

ER -